Free Trial

Investors Buy Large Volume of Put Options on Vor Biopharma (NYSE:VOR)

Vor Biopharma logo with Medical background

Vor Biopharma Inc. (NYSE:VOR - Get Free Report) saw some unusual options trading on Tuesday. Investors bought 17,569 put options on the stock. This represents an increase of approximately 345% compared to the typical daily volume of 3,949 put options.

Analysts Set New Price Targets

Several research analysts have issued reports on VOR shares. HC Wainwright upgraded Vor Biopharma from a "neutral" rating to a "buy" rating and set a $3.00 price target on the stock in a report on Monday, June 30th. JMP Securities reaffirmed a "market perform" rating and set a $6.00 price target on shares of Vor Biopharma in a research report on Friday, May 9th. Oppenheimer reaffirmed an "outperform" rating and set a $8.00 price target on shares of Vor Biopharma in a research report on Friday, March 21st. Stifel Nicolaus decreased their price target on Vor Biopharma from $12.00 to $5.00 and set a "buy" rating for the company in a research report on Friday, March 21st. Finally, Citizens Jmp downgraded Vor Biopharma from a "strong-buy" rating to a "hold" rating in a research report on Friday, May 9th. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $5.63.

Get Our Latest Stock Analysis on Vor Biopharma

Vor Biopharma Price Performance

NYSE:VOR traded up $0.19 during mid-day trading on Wednesday, reaching $2.59. 14,804,557 shares of the company's stock traded hands, compared to its average volume of 4,595,034. Vor Biopharma has a 12-month low of $0.13 and a 12-month high of $3.29. The firm has a market capitalization of $323.40 million, a price-to-earnings ratio of -1.59 and a beta of 2.04. The company has a 50 day moving average price of $0.53 and a 200-day moving average price of $0.87.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. GABELLI & Co INVESTMENT ADVISERS INC. purchased a new position in Vor Biopharma during the 4th quarter valued at about $33,000. Money Concepts Capital Corp increased its holdings in Vor Biopharma by 106.1% during the 1st quarter. Money Concepts Capital Corp now owns 51,535 shares of the company's stock valued at $37,000 after purchasing an additional 26,535 shares during the period. Virtu Financial LLC purchased a new position in Vor Biopharma during the 4th quarter valued at about $60,000. XTX Topco Ltd purchased a new position in Vor Biopharma during the 4th quarter valued at about $80,000. Finally, Goldman Sachs Group Inc. grew its holdings in shares of Vor Biopharma by 218.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company's stock worth $61,000 after acquiring an additional 58,247 shares during the period. Hedge funds and other institutional investors own 97.29% of the company's stock.

About Vor Biopharma

(Get Free Report)

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.

Further Reading

Should You Invest $1,000 in Vor Biopharma Right Now?

Before you consider Vor Biopharma, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vor Biopharma wasn't on the list.

While Vor Biopharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead
3 Made in America Stocks Under $20 You Need to See!
3 Cheap Growth Stocks Set to Explode This Summer

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines